

How conformational changes can affect catalysis, inhibition and drug resistance of enzymes with induced-fit binding mechanism such as the HIV-1 protease

Thomas R. Weikl^a, Bahram Hemmateenejad^{a,b}

^aMax Planck Institute of Colloids and Interfaces, Department of Theory and Bio-Systems, Potsdam, Germany

^bDepartment of Chemistry, Shiraz University, Shiraz, Iran

Abstract

A central question is how the conformational changes of proteins affect their function and the inhibition of this function by drug molecules. Many enzymes change from an open to a closed conformation upon binding of substrate or inhibitor molecules. These conformational changes have been suggested to follow an induced-fit mechanism in which the molecules first bind in the open conformation in those cases where binding in the closed conformation appears to be sterically obstructed such as for the HIV-1 protease. In this article, we present a general model for the catalysis and inhibition of enzymes with induced-fit binding mechanism. We derive general expressions that specify how the overall catalytic rate of the enzymes depends on the rates for binding, for the conformational changes, and for the chemical reaction. Based on these expressions, we analyze the effect of mutations that mainly shift the conformational equilibrium on catalysis and inhibition. If the overall catalytic rate is limited by product unbinding, we find that mutations that destabilize the closed conformation relative to the open conformation increase the catalytic rate in the presence of inhibitors by a factor $\exp(\Delta\Delta G_C/RT)$ where $\Delta\Delta G_C$ is the mutation-induced shift of the free-energy difference between the conformations. This increase in the catalytic rate due to changes in the conformational equilibrium is independent of the inhibitor molecule and, thus, may help to understand how non-active-site mutations can contribute to the multi-drug-resistance that has been observed for the HIV-1 protease. A comparison to experimental data for the non-active-site mutation L90M of the HIV-1 protease indicates that the mutation slightly destabilizes the closed conformation of the enzyme.

Keywords: enzyme dynamics, induced fit, conformational selection, HIV-1 protease, non-active-site mutation, multi-drug resistance

1. Introduction

The function of proteins often involves conformational changes during the binding or unbinding of ligand molecules [1, 2]. Central questions are how these conformational changes are coupled to the binding processes, and how they affect the function of the proteins and the inhibition of this function by drug molecules. For some proteins, a conformational change has been proposed to occur *predominantly after* a binding or unbinding process [3–6], apparently ‘induced’ by this process [7]. For other proteins, a conformational change has been suggested to occur *predominantly prior* to a binding or unbinding process [8–16], which has been termed ‘conformational selection’ since the ligand appears to select a conformation for binding or unbinding [17–19]. Binding *via* conformational selection implies induced-change unbinding, and *vice versa*, since the ordering of events is reversed in the binding and unbinding direction [16].

In this article, we extend classical models of enzyme catalysis and inhibition [20] by including a conformational change during the binding and unbinding of substrate, product, or inhibitor molecules. Our aim is to investigate how the conformational change affects the catalytic rates in the presence and absence of inhibitor molecules, and how non-active-site mutations that shift the conformational equilibrium alter these catalytic rates. We focus on enzymes with induced-change bind-

ing mechanism since many enzymes close rather tightly over substrate or inhibitor molecules during binding. Binding via an induced-change mechanism, i.e. prior to the change from the ‘open’ to the ‘closed’ conformation of these enzymes, is required if the entry and exit of the ligand molecules are sterically obstructed in the closed conformation [3]. In the reverse direction, the ligands then unbind *via* conformational selection because the change from the closed to open conformation has to occur prior to the unbinding process. Classical models of competitive inhibition, in which the inhibitor binds to the same site as the substrate, involve four states: an empty state E of the enzyme, and three states ES , EP , and EI in which the enzyme is bound to a substrate molecule S , a product molecule P , or an inhibitor molecule I [20]. In our extended model for enzymes with induced-change binding mechanism, the enzyme can adopt two conformations, an ‘open’ conformation 1, and a ‘closed’ conformation 2. The model has seven states because induced-change binding involves an open state E_1S and a closed state E_2S with bound substrate, two such states E_1P and E_2P with bound product, and two states E_1I and E_2I with bound inhibitor, besides the empty state (see fig. 1).

With our extended model, we derive general expressions for the catalytic rates of enzymes with induced-change binding mechanism. The catalytic rates of these enzymes depend on (i) the binding and unbinding rates of substrate, product, and in-




Figure 1: 7-state model for catalysis and inhibition of an enzyme with induced-fit binding mechanism. In this model, substrate molecules S and inhibitor molecules I first bind in conformation E_1 of the enzyme. These binding events induce changes into conformation E_2 in which the substrate S is converted into the product P . In the case of the HIV-1 protease, the conformation E_1 corresponds to the semi-open conformation, and the conformation E_2 to the closed conformation.

inhibitor molecules in the open conformation 1, (ii) the forward and backward rates of the catalytic step, and (iii) the transition rates between the two conformations in the bound states of the enzyme (see eqs. (2) to (8)). Our general expressions for the catalytic rates lead to an effective four-state model with a single substrate-bound state, a single product-bound, and a single inhibitor-bound state (see fig. 2), but with effective on- and off-rates of substrate and product molecules that depend on the conformational transition rates (see eqs. (6) to (8)).

The role of the conformational changes for catalysis and inhibition can be revealed by non-active-site mutations that slightly shift the conformational equilibrium, but do not interfere directly with binding and catalysis in the active site of the enzymes. Several groups have suggested that such shifts in the conformational equilibrium might explain why non-active-site mutations can contribute to multi-drug resistance [36, 42, 43], i.e. to an increase of catalytic rates in the presence of different inhibitory drugs. Based on our general results for enzymes with induced-change binding mechanism, we investigate how these mutations affect catalysis and inhibition, and distinguish two cases. In case 1, the maximum catalytic rate of the enzyme is limited by the unbinding of the product. We find that the catalytic rate in the presence of inhibitors depends exponentially on the mutation-induced change $\Delta\Delta G_C$ of the free-energy difference between the two conformations of the enzyme in this case (see eqs. (25) and (27)). Non-active-site mutations with $\Delta\Delta G_C > 0$ that slightly destabilize the closed conformation 2 relative to the open conformation 1 of the enzyme lead to an increase in the catalytic rate, irrespective of the inhibitor. Such non-active-site mutations thus contribute to a multi-drug-resistance of the enzyme. In case 2, the maximum catalytic rate of the enzyme is limited by the forward rate of the catalytic step. In this case, mutation-induced changes of the conformational equilibrium have no effect on the catalytic rate in the

presence of inhibitors. A comparison with experimental data for the non-active-site mutation L90M of the HIV-1 protease indicates that this enzyme appears to follow case 1, which implies that non-active-site mutations that slightly destabilize the closed conformation contribute to multi-drug resistance.

2. Catalysis and inhibition of an enzyme with induced-fit binding mechanism

We consider an enzyme with two conformations E_1 and E_2 that binds its substrate S via an induced-change mechanism $E_1 \rightleftharpoons E_1S \rightleftharpoons E_2S$. We assume that the catalytic step occurs in conformation 2 of the enzyme, and that the inhibitor I binds to the same site as the substrate ('competitive inhibition'). The catalytic cycle of the enzyme and the inhibition of this cycle then can be described by the 7-state model shown in fig. 1.

The catalytic rate depends on the 14 forward and backward rates between the 7 states of the model. These rates are:

- (i) The *binding rates* $s_+[S]$, $p_+[P]$, and $i_+[I]$ and *unbinding rates* s_- , p_- , and i_- of substrate, product and inhibitor molecules in conformation 1 of the enzyme. Here, $[S]$, $[P]$, and $[I]$ denote the concentrations of these molecules.
- (ii) The forward and reverse *rates of the catalytic step* k_f and k_r .
- (iii) The *conformational transition rates* s_{12} , s_{21} , p_{12} , p_{21} , i_{12} and i_{21} between the substrate-bound states E_1S and E_2S , product-bound states E_1P and E_2P , and inhibitor-bound states E_1I and E_2I . We assume that the bound states E_2S , E_2P , and E_2I with conformation 2 of the enzyme are the ground-state conformations, while the conformations E_1S , E_1P , and E_1I with conformation 1 of the enzyme are excited-state conformations. This assumption is valid if experimental structures indicate that an enzyme adopts conformation 1 in its unbound state and conformation 2 in its bound states, since the experimental




Figure 2: Effective 4-state model for catalysis and inhibition of an enzyme with induced-fit binding mechanism. The effective binding and unbinding rates of substrate and product given in eqs. (6) to (8) connect this model to the 7-state model of fig. 1.

structures correspond to ground-state conformations. The assumption implies

$$s_{21} \ll s_{12}, \quad p_{21} \ll p_{12}, \quad \text{and} \quad i_{21} \ll i_{12} \quad (1)$$

i.e. the excitation rates s_{21} , p_{21} , and i_{21} are much smaller than the corresponding ground-state relaxation rates s_{12} , p_{12} , and i_{12} .

One of our main results is that the catalytic rate can be written in the Michaelis-Menten form (see Appendix A)

$$k \simeq \frac{k_{\max}[S]}{(1 + [I]/K_i)K_m + [S]} \quad (2)$$

with

$$k_{\max} \simeq \frac{k_f p_{\text{of}}}{k_f + k_r + p_{\text{of}}} \quad (3)$$

$$K_m \simeq \frac{(k_f + s_{\text{of}})p_{\text{of}} + k_r s_{\text{of}}}{(k_f + k_r + p_{\text{of}})s_{\text{on}}} \quad (4)$$

$$K_i = \frac{i_{21}i_-}{i_{12}i_+} \quad (5)$$

and

$$s_{\text{on}} = \frac{s_{12}s_+}{s_{12} + s_-} \quad (6)$$

$$s_{\text{of}} = \frac{s_{21}s_-}{s_{12} + s_-} \quad (7)$$

$$p_{\text{of}} = \frac{p_{21}p_-}{p_{12} + p_-} \quad (8)$$

for negligible product concentration $[P]$ or negligible product binding rate $p_+[P]$. In deriving eqs. (2) to (8) from the exact solution, we have assumed that the excitation rate p_{21} in the product-bound state is much smaller than the relaxation rate s_{12} in the substrate-bound state, besides eq. (1) (see Appendix A). This assumption is reasonable if the relaxation rates s_{12} and p_{12} in the substrate- and product-bound states are of similar magnitude, since $p_{21} \ll p_{12}$ (see eq. (1)) then implies also $p_{21} \ll s_{12}$.

Our general results for the 7-state model of fig. 1 lead to an effective 4-state model of catalysis and inhibition, see fig. 2. The catalytic rate of this 4-state model is described by eqs. (2) to (4) with $K_i = i_{\text{of}}/i_{\text{on}}$ for negligible product concentration $[P]$. The effective 4-state model has the same structure as classical 4-state models for competitive inhibition [20], but includes two conformations for the enzyme. The rates s_{on} and s_{of} in eqs. (6) and (7) can be understood as the effective on- and off-rates of the substrate, i.e. as the effective forward and backward rates between the unbound state E_1 and the bound ground state E_2S . Similarly, p_{of} in eq. (8) can be understood as the effective unbinding rate of the product from the bound ground state E_2P . The expressions in eqs. (6) and (8) for the effective on- and off-rates result here from an analysis of steady-state catalytic rates, but are identical with previously derived expressions for the effective relaxation rates of two-step binding processes that involve a conformational change [16, 56] (see appendix B).

3. Effect of non-active site mutations on catalysis

In general, mutations can affect all rate constants of the 7-state model shown in fig. 1, in particular if they are located in the binding site, or active site, of the enzyme. Non-active-site mutations, in contrast, may mainly affect the conformational equilibrium of the bound ground states and excited states. The conformational equilibrium constant s_{21}/s_{12} of the two substrate-bound states E_1S and E_2S and the equilibrium constant p_{21}/p_{12} of the product-bound states E_1P and E_2P depend on the free-energy energy differences between the states. These differences can be decomposed into the free-energy difference $\Delta G_C = G(E_2) - G(E_1)$ between the conformations and the differences in the binding free energy of substrate and product molecules in the two conformations of the enzyme. If a non-active-site mutation only affects the conformational free-energy difference but not the binding free-energy differences between the conformations, we have

$$\frac{s'_{21}/s'_{12}}{s_{21}/s_{12}} = \exp(\Delta\Delta G_C/RT) \quad (9)$$

$$\frac{p'_{21}/p'_{12}}{p_{21}/p_{12}} = \exp(\Delta\Delta G_C/RT) \quad (10)$$

where the prime indicates rates of the mutant. Here, $\Delta\Delta G_C = \Delta G'_C - \Delta G_C$ is the mutation-induced change of the free-energy difference between the conformations.

If the relaxation rates s_{12} and p_{12} into the bound ground states are much larger than the corresponding unbinding rates s_- and p_- from the excited states, we obtain

$$\frac{s'_{\text{on}}}{s_{\text{on}}} \simeq 1 \quad (11)$$

$$\frac{s'_{\text{of}}}{s_{\text{of}}} \simeq \exp(\Delta\Delta G_C/RT) \quad (12)$$

$$\frac{p'_{\text{of}}}{p_{\text{of}}} \simeq \exp(\Delta\Delta G_C/RT) \quad (13)$$

from eqs. (6) to (8), which simplify to $s_{\text{on}} \simeq s_+$, $s_{\text{of}} \simeq s_{21}s_-/s_{12}$, and $p_{\text{of}} \simeq p_{21}p_-/p_{12}$ in this case. We have assumed here that the non-active-site mutation does not affect the binding and unbinding rate constants s_+ , s_- , and p_- . Alternatively, the eqs. (11) and (13) follow from the eqs. (6) to (8) if we assume that the mutation-induced change of the conformational free-energy difference mainly affects the excitation rates, which implies $s'_{21}/s_{21} \simeq \exp(\Delta\Delta G_C/RT)$ and $s'_{12} \simeq s_{12}$ for the conformational transition rates of the substrate-bound states, and $p'_{21}/p_{21} \simeq \exp(\Delta\Delta G_C/RT)$ and $p'_{12} \simeq p_{12}$ for the transition rates of the product-bound states [16]. The non-active-site mutation thus changes the effective off-rates of substrate and product molecules by the same factor $\exp(\Delta\Delta G_C/RT)$, irrespective of the binding energies of these molecules, while the effective on-rates remain the same.

With eqs. (11) to (13), we can now determine the effect of a non-active-site mutation on the catalytic quantities k_{max} and K_m of the enzyme, which are given in eqs. (3) and (4). We assume that the non-active-site mutation does not affect the forward and backward rates k_f and k_r of the catalytic step, and consider two cases:

Case 1: k_f much larger than p_{of} and s_{of}

If the forward rate k_f of the catalytic step is much larger than the effective off-rates of product and substrate, we obtain

$$k_{\text{max}} \simeq \frac{k_f p_{\text{of}}}{k_f + k_r} \quad (14)$$

$$K_m \simeq \frac{k_f p_{\text{of}} + k_r s_{\text{of}}}{(k_f + k_r) s_{\text{on}}} \quad (15)$$

from eqs. (3) and (4). The effect of the non-active-site mutation on k_{max} and K_m is then characterized by (see eqs. (11) to (13))

$$\frac{k'_{\text{max}}}{k_{\text{max}}} \simeq \frac{p'_{\text{of}}}{p_{\text{of}}} \simeq \exp(\Delta\Delta G_C/RT) \quad (16)$$

and

$$\frac{K'_m}{K_m} \simeq \frac{k_f p'_{\text{of}} + k_r s'_{\text{of}}}{k_f p_{\text{of}} + k_r s_{\text{of}}} \simeq \exp(\Delta\Delta G_C/RT) \quad (17)$$

for $k'_f \simeq k_f$ and $k'_r \simeq k_r$. The non-active-site mutation thus changes k_{max} and K_m by the same factor $\exp(\Delta\Delta G_C/RT)$. The ratio k_{max}/K_m of these quantities therefore is not affected by the mutation:

$$\frac{k'_{\text{max}}}{K'_m} \simeq \frac{k_{\text{max}}}{K_m} \quad (18)$$

Case 2: k_f and k_r much smaller than p_{of} and s_{of}

If the rates k_f and k_r for the catalytic step are much smaller than the effective off-rates of substrate and product, we obtain

$$k_{\text{max}} \simeq k_f \quad (19)$$

$$K_m \simeq \frac{s_{\text{of}}}{s_{\text{on}}} \quad (20)$$

from eqs. (3) and (4). The effect of the non-active-site mutation then can be described by

$$\frac{k'_{\text{max}}}{k_{\text{max}}} \simeq 1 \quad (21)$$

and

$$\frac{K'_m}{K_m} \simeq \frac{s'_{\text{of}}}{s_{\text{of}}} \simeq \exp(\Delta\Delta G_C/RT) \quad (22)$$

The non-active-site mutation thus changes K_m by the same factor as in case 1, but does not affect the maximal catalytic rate k_{max} . From these equations, we obtain

$$\frac{k'_{\text{max}}/K'_m}{k_{\text{max}}/K_m} \simeq \exp(-\Delta\Delta G_C/RT) \quad (23)$$

4. Effect of non-active-site mutations on inhibition

To quantify the effect of a non-active-site mutation on the interplay of catalysis and inhibition, we focus now on substrate and inhibitor concentrations $[I]$ and $[S]$ with $[I] \gg K_i$ and $[I]K_m/K_i \gg [S]$. For such concentrations, a substantial fraction of the enzyme is bound to the inhibitor, and the catalytic rate of the enzyme is (see eq. (2))

$$k \simeq \frac{k_{\text{max}} K_i [S]}{K_m [I]} \quad (24)$$

and, thus, proportional to the inhibition constant K_i and inversely proportional to the inhibitor concentration $[I]$. For $[I] \ll K_i$ or $[I]K_m/K_i \ll [S]$, in contrast, the catalytic rate of the enzyme is independent of $[I]$ and K_i (see eq. (2)). If the mutant also fulfills the conditions $[I] \gg K'_i$ and $[I]K'_m/K'_i \gg [S]$ at the considered substrate and inhibitor concentrations, the ratio of the catalytic rates of mutant and wildtype is

$$\frac{k'}{k} \simeq \frac{K'_i k'_{\text{max}}/K'_m}{K_i k_{\text{max}}/K_m} \quad (25)$$

The expression on the right-hand side of this equation has been termed the ‘vitality’ of the mutant [21]. The vitality depends on the catalytic quantities k_{max} and K_m and on the inhibition constant K_i of the wildtype and mutant enzyme.

The inhibition constant K_i , defined in eq. (5), is the dissociation constant of the inhibitor and the enzyme. The constant depends on the free-energy difference $G(E_2I) - G(E_1)$ between the bound ground state E_2I and the unbound state E_1 . This free-energy difference can be composed into the free-energy difference $\Delta G_C = G(E_2) - G(E_1)$ between the conformations of the enzyme, and the binding energy $\Delta G_I = G(E_2I) - G(E_2)$ in conformation 2 of the enzyme. The effect of a mutation on K_i thus can be characterized by

$$\frac{K'_i}{K_i} = \exp((\Delta\Delta G_C + \Delta\Delta G_I)/RT) \quad (26)$$

where K'_i is the inhibition constant of the mutant, and $\Delta\Delta G_C$ and $\Delta\Delta G_I$ are the mutation-induced changes of the conformational free-energy difference and the binding free energy in

conformation 2. Besides affecting ΔG_c , some non-active-site mutations that contribute to inhibitor resistance of an enzyme have been suggested to have an indirect effect on the binding free energy ΔG_I by slightly changing the shape of the binding pocket in a way that does not interfere with substrate binding [22–24]. This suggestion concerns inhibitors with a bound shape that is not confined within the shape or ‘envelope’ of the bound substrate.

With eq. (26) and the results of the previous section, we can now determine the vitality of non-active site mutants. We consider again the two cases of the previous section:

Case 1: k_f much larger than p_{of} and s_{of}

If the forward rate of the catalytic step is much larger than the effective off-rates of product and substrate for both wildtype and mutant, we obtain the vitality

$$\frac{K'_i k'_{\max}/K'_m}{K_i k_{\max}/K_m} \simeq \exp((\Delta\Delta G_C + \Delta\Delta G_I)/RT) \quad (27)$$

from the eqs. (18) and (26). The effect of the non-active-site mutation on the free-energy difference between the conformation thus is reflected by the factor $\exp(\Delta\Delta G_C/RT)$ in the vitality, while the effect of the mutation on the binding-free energy of the inhibitor in conformation 2 of the enzyme is reflected by the factor $\exp(\Delta\Delta G_I/RT)$. Eq. (27) indicates that the change of the conformational free-energy difference induced by a non-active-site mutation can have a significant effect on the catalytic rate of the mutant in the presence of the inhibitors.

Case 2: k_f and k_r much smaller than p_{of} and s_{of}

If the rates for the catalytic step are much smaller than the effective off-rates of substrate and product, we obtain the vitality

$$\frac{K'_i k'_{\max}/K'_m}{K_i k_{\max}/K_m} \simeq \exp(\Delta\Delta G_I/RT) \quad (28)$$

from the eqs. (23) and (26). In this case, the vitality is only affected by the change $\Delta\Delta G_I$ in the binding-free energy of the inhibitor.

5. Comparison with experimental data for the non-active site mutation L90M of the HIV-1 protease

To illustrate our general results for the effect of non-active-site mutations on catalysis and inhibition of enzymes with induced-fit binding kinetics, we consider here the well-studied mutation L90M of the HIV-1 protease as an example. The HIV-1 protease changes from a semi-open to a closed conformation during binding of substrate or inhibitor molecules. The conformational change from the semi-open to the closed conformation has been suggested to occur after the binding process since binding in the closed conformation appears to be sterically prohibited [25, 26]. The conformational dynamics of the HIV-1 protease has been studied in NMR experiments [27–29], by pulsed EPR spectroscopy [30–32], and in molecular dynamics simulations [33–41]. In the native state, the HIV-1 protease

Table 1: Catalytic efficiency of mutant L90M relative to wildtype HIV-1 protease (data from Maschera et al.[42])

substrate	$\frac{k'_{\max}}{k_{\max}}$	$\frac{K'_m}{K_m}$	$\frac{k'_{\max}/K'_m}{k_{\max}/K_m}$
SQNY-PIVQ	1.3	1.4	0.9
ARVL-AEAM	1.6	1.3	1.3
ATIM-MQRG	1.4	1.6	0.9
PGNF-LQSR	–	–	0.4
SFNF-PQIT	1.3	1.9	0.8
TLNF-PISP	1.2	1.1	1.1
AETF-YVDG	1.4	1.2	1.2
RKIL-FLDG	1.2	0.9	1.5
fluorogenic	1.4	2	0.7

is a homo-dimer of two identical subunits with 99 residues. The active site is located in a tunnel at the dimer interface, which opens and closes *via* the motion of two ‘flaps’, accompanied by motion in other regions of the protease. Inhibitors of the HIV-1 protease that bind to the active site play a central role in anti-AIDS therapies. However, the efficiency of these therapies is impaired by viral mutations that lead to inhibitor resistance. Mutations that are associated with resistance occur both in the active site of the HIV-1 protease and distal to the active site. While active-site mutations can directly interfere with catalysis and binding, the contribution of distal, non-active-site mutations to resistance is not fully clear. Several groups have suggested that non-active-site mutations of the HIV-1 protease such as L90M contribute to inhibitor resistance by shifting the equilibrium between the semi-open and closed conformation of the protease [36, 42, 43]. Alternative explanations for the mutation L90M include an indirect effect on active-site residues [44–47], and a reduction of dimer stability [48] since the mutated residue 90 is located at the dimer interface.

Maschera and co-workers [42] have systematically investigated the catalytic efficiency of the wildtype protease and the mutant L90M with 8 different peptide substrates and a fluorogenic substrate (see Table 1). The mutation L90M leads to a slight increase of k_{cat} and K_m . Averaged over all substrates, the ratios of the experimental values for the mutant and the wildtype are $k'_{\max}/k_{\max} = 1.35 \pm 0.05$ and $K'_m/K_m = 1.43 \pm 0.14$, while the average value for the ratio of k'_{\max}/K'_m and k_{\max}/K_m is 0.98 ± 0.12 . These results are consistent with eqs. (16) to (18), which indicate a change of k_{cat} and K_m by the same factor $\exp(\Delta\Delta G_C/RT)$ due to a non-active-site mutation that mainly affects the conformational equilibrium. From the average values of k'_{\max}/k_{\max} and K'_m/K_m obtained from the data of Maschera et al., the change in the conformational free-energy difference $\Delta\Delta G_C$ due to the mutation L90M can be estimated as about 0.2 kcal/mol, which indicates a slight destabilization of the closed conformation of the HIV-1 protease relative to the semi-open conformation. However, other groups have reported a decrease of k_{\max} , K_m , and k_{\max}/K_m due to the mutation L90M for three different substrates [49–51]. In general,

Table 2: Ratio of dissociation constants K'_D and K_D for the mutant L90M and the wildtype of the HIV-1 protease (calculated from data of Shuman et al.[54])

inhibitor	K'_D/K_D
Amprenavir	2.73 ± 0.67
Indinavir	2.85 ± 0.71
Nelfinavir	1.99 ± 0.70
Ritonavir	4.54 ± 1.68
Saquinavir	2.93 ± 0.77

the catalytic efficiency of the HIV-1 protease strongly depends on the experimental conditions, in particular on the pH and salt concentration [42, 52, 53].

Shuman et al. [54] have measured the dissociation constants K_D and K'_D of the wildtype and the mutant L90M for five different inhibitors with biosensor methods (see Table 2). Within the experimental errors, the ratios K'_D/K_D of the dissociation constants for the five inhibitors agree with the average value 3.0 ± 0.4 of these ratios. For a non-active-site mutation with a negligible change $\Delta\Delta G_I$ of the binding free energy in the closed conformation of the protease, we expect a change of K_D by the inhibitor-independent factor $\exp(\Delta\Delta G_C/RT)$ from eq. (26) since K_D is identical with the inhibition constant K_i . From the mean value $K'_D/K_D \simeq 3$, we obtain the estimate $\Delta\Delta G_C \simeq 0.65$ kcal/mol for $\Delta\Delta G_I \simeq 0$, which is somewhat larger than the estimate $\Delta\Delta G_C \simeq 0.2$ kcal/mol obtained from the changes of k_{\max} and K_m reported by Maschera et al. (see above).

Inhibition constants K_i and K'_i for the wildtype and mutant L90M have been measured by several groups for a variety of inhibitors (see Table 3). The ratios K'_i/K_i differ for different inhibitors, which appears to indicate mutation-induced changes $\Delta\Delta G_I$ in the binding free energy for the closed conformation that depend on the inhibitor. However, results by different groups for the same inhibitor also differ (see data in Table 3 for the inhibitors Indinavir and Saquinavir), possibly due to different experimental conditions such as pH or salt concentrations. Overall, the majority of the experimentally determined ratios K'_i/K_i for L90M in Table 3 are larger than 1, which may be interpreted to point towards a destabilization of the closed conformation relative to the semi-open, i.e. towards positive values of $\Delta\Delta G_C$.

6. Conclusions

We have considered here a general 7-state model for the catalysis and inhibition of enzymes with induced-fit binding mechanism. This model extends classical models for catalysis and inhibition [20] by including changes between two different conformations of the enzymes, and helps to understand how non-active-site mutations that shift the conformational equilibrium can affect catalysis and inhibition. The induced-fit binding mechanism considered here applies to enzymes such as the HIV-1 protease that close over ligands in the bound ground-state conformation in a way that sterically prevents ligand exit

Table 3: Ratio of inhibition constants K'_i and K_i for the mutant L90M and the wildtype of the HIV-1 protease

inhibitor	reference	K'_i/K_i	
Indinavir	[50]	4.1 ± 0.8	
	[47]	1.3 ± 0.3	
	[49]	0.16 ± 0.03	
Nelfinavir	[50]	9.0 ± 1.5	
	Ritonavir	[50]	3.2 ± 1.0
	Saquinavir	[42]	21 ± 4
L-735,524	[50]	28 ± 9	
	[57]	3.0 ± 1.0	
	[42]	5.8 ± 1.7	
VX-478	[42]	2.7 ± 0.3	
AG-1343	[42]	3.5 ± 1.0	
ABT-538	[42]	6.7 ± 2.4	
Lopinavir	[50]	1.0 ± 0.6	
QF34	[50]	0.9 ± 0.4	
Darunavir (TMC-114)	[47]	0.14 ± 0.04	

and entry in this conformation [3, 25, 26]. The unbinding of product and inhibitor molecules from these enzymes follows a conformational-selection mechanism since a conformational change from the closed ground-state conformation to an open or semi-open excited-state conformation is required prior to ligand exit [16]. Our approach can be generalized to enzymes with other binding mechanisms, e.g. to enzymes with a conformation-selection binding and induced-fit unbinding mechanism.

Acknowledgements

Support from the Alexander von Humboldt Foundation via a Georg Forster Research Fellowship for Bahram Hemmateenejad and from the Shiraz University Research Council are gratefully acknowledged.

Appendix A. Catalytic rates

We illustrate in this section how eqs. (2) to (8) for the catalytic rate of the 7-state model shown in fig. 1 can be derived from exact results. To avoid exceedingly long equations, we focus on the special case with inhibitor concentration $[I] = 0$. The derivation in the general case with $[I] > 0$ is analogous to the derivation in this special case.

For $[I] = 0$, the two states E_1I and E_2I have zero probability. The 7-state model thus reduces to a model with 5 states. The steady-state probabilities $P(E_1)$, $P(E_1S)$, $P(E_2S)$, $P(E_2P)$, and $P(E_1P)$ of these 5 states can be calculated from the 5 equations (see e.g. [55])

$$P(E_1) + P(E_1S) + P(E_2S) + P(E_2P) + P(E_1P) = 1 \quad (\text{A.1})$$

$$P(E_1S)s_- + P(E_1P)p_- - P(E_1)s_+[S] = 0 \quad (\text{A.2})$$

$$P(E_1)s_+[S] + P(E_2S)s_{21} - P(E_1S)(s_{12} + s_-) = 0 \quad (\text{A.3})$$

$$P(E_1S)s_{12} + P(E_2P)k_r - P(E_2S)(s_{21} + k_f) = 0 \quad (\text{A.4})$$

$$P(E_2S)k_f + P(E_1P)p_{12} - P(E_2P)(k_r + p_{21}) = 0 \quad (\text{A.5})$$

While eq. (A.1) ensures probability normalization, the eqs. (A.2) to (A.5) are the flux balance conditions for the states E_1 , E_1S , E_2S , and E_2P in the steady state, in which the inward flux into a state equals the outward flux from this state. We have assumed that the product concentration $[P]$ or product binding rate $p_+[P]$ are negligible in eq. (A.2).

The catalytic flux k of the enzyme is defined as the steady-state flux along the cycle:

$$k = P(E_2S)k_f - P(E_2P)k_r \quad (\text{A.6})$$

From eqs. (A.1) to (A.6), we obtain the exact result for catalytic flux

$$k = \frac{a[S]}{b + c[S]} \quad (\text{A.7})$$

with

$$a = s_+s_{12}k_f p_{21}p_- \quad (\text{A.8})$$

$$b = k_f p_{21}p_- (s_{12} + s_-) + k_r s_{21} s_- (p_{12} + p_-) + s_{21} s_- p_{21} p_- \quad (\text{A.9})$$

$$c = k_f (p_{21}p_- + (p_{12} + p_{21} + p_-)s_{12})s_+ + (k_r (p_{12} + p_-) + p_{21}p_-)(s_{12} + s_{21})s_+ \quad (\text{A.10})$$

For $p_{21} \ll p_{12}$ and $s_{21} \ll s_{12}$ (see eq. (1)), eq. (A.10) can be simplified to

$$c \simeq k_f ((p_{21} + s_{12})p_- + p_{12}s_{12})s_+ + (k_r (p_{12} + p_-) + p_{21}p_-)s_{12}s_+ \quad (\text{A.11})$$

If we further assume $p_{21} \ll s_{12}$ (see text after eq. (8) for justification), we obtain

$$c \simeq ((k_f + k_r)(p_{12} + p_-) + p_{21}p_-)s_{12}s_+ \quad (\text{A.12})$$


The eqs. (A.8) and (A.12) now lead to the maximal catalytic flux

$$k_{\max} = \frac{a}{c} \simeq \frac{k_f p_{21} p_-}{(k_f + k_r)(p_{12} + p_-) + p_{21} p_-} \quad (\text{A.13})$$

This expression for the maximal catalytic flux is identical to eq. (3) with p_{of} given in eq. (8). Similarly, the eqs. (A.9) and (A.12) lead to an expression for $K_m = b/c$ that is identical to eq. (4) with eqs. (6) to (8).

Appendix B. Effective rates for induced-fit binding

We consider here the induced-fit binding process of an inhibitor I to an enzyme that can adopt two conformations E_1 and E_2 :



In the forward direction of this process, the conformational change occurs after the binding event, apparently ‘induced’ by this event. In the reverse direction, the conformational change precedes the

unbinding step. The unbinding of the inhibitor thus follows a conformational-selection mechanism. Here, i_+ and i_- are the rate constants for the binding and unbinding of the inhibitor in conformation 1 of the enzyme, and i_{12} and i_{21} are rates for the conformational exchange between the bound ground state E_2I and the bound excited state E_1I . We assume that the concentration $[I]$ of the inhibitor is much larger than the enzyme concentration, which implies pseudo-first-order kinetics with approximately constant inhibitor concentration and, thus, constant binding rate $i_+[I]$.

The effective on- and off-rates of the two-step process (B.1) can be determined from the dominant relaxation rate of this process [16, 56]. Since the excitation rate i_{21} of the bound excited state E_1I is much smaller than the relaxation rate i_{12} into the bound ground state E_2I , the effective off-rate from E_2I to E_1 is [16, 56]:

$$i_{\text{of}} \simeq \frac{i_{21}i_-}{i_{12} + i_-} \quad (\text{B.2})$$

The effective on-rate i_{on} follows from the condition that the effective equilibrium constant $i_{\text{on}}/i_{\text{of}}$ of the two-step process has to be equal to the product $(i_+/i_-)(i_{12}/i_{21})$ of the equilibrium constants for the two substeps. With eq. (B.2), this condition leads to

$$i_{\text{on}} \simeq \frac{i_{12}i_+}{i_{12} + i_-} \quad (\text{B.3})$$

References

- [1] M. Gerstein, W. Krebs, A database of macromolecular motions, *Nucleic Acids Res.* 26 (1998) 4280–4290.
- [2] C.-S. Goh, D. Milburn, M. Gerstein, Conformational changes associated with protein-protein interactions, *Curr. Opin. Struct. Biol.* 14 (2004) 104–109.
- [3] S. M. Sullivan, T. Holyoak, Enzymes with lid-gated active sites must operate by an induced fit mechanism instead of conformational selection, *Proc. Natl. Acad. Sci. USA* 105 (2008) 13829–13834.
- [4] M. Elinder, P. Selhorst, G. Vanham, B. Oberg, L. Vrang, U. H. Danielson, Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy, *Biochem. Pharmacol.* 80 (2010) 1133–1140.
- [5] S. Fieulaine, A. Boularot, I. Artaud, M. Desmadril, F. Dardel, T. Meinnel, C. Giglione, Trapping conformational states along ligand-binding dynamics of peptide deformylase: The impact of induced fit on enzyme catalysis, *PLoS Biol.* 9 (2011) e1001066.
- [6] R. A. Copeland, Conformational adaptation in drug-target interactions and residence time, *Future Med. Chem.* 3 (2011) 1491–1501.
- [7] D. E. Koshland, Application of a theory of enzyme specificity to protein synthesis, *Proc. Natl. Acad. Sci. USA* 44 (1958) 98–104.
- [8] H. Beach, R. Cole, M. Gill, J. Loria, Conservation of μ s-ms enzyme motions in the apo- and substrate-mimicked state, *J. Am. Chem. Soc.* 127 (2005) 9167–9176.
- [9] D. D. Boehr, D. McElheny, H. J. Dyson, P. E. Wright, The dynamic energy landscape of dihydrofolate reductase catalysis, *Science* 313 (2006) 1638–1642.
- [10] Y. B. Kim, S. S. Kalinowski, J. Marcinkeviciene, A pre-steady state analysis of ligand binding to human glucokinase: Evidence for a preexisting equilibrium, *Biochemistry* 46 (2007) 1423–1431.
- [11] L. Qiu, M. Gulotta, R. Callender, Lactate dehydrogenase undergoes a substantial structural change to bind its substrate, *Biophys. J.* 93 (2007) 1677–1686.
- [12] O. F. Lange, N.-A. Lakomek, C. Fares, G. F. Schröder, K. F. A. Walter, S. Becker, J. Meiler, H. Grubmüller, C. Griesinger, B. L. de Groot, Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution, *Science* 320 (2008) 1471–1475.

- [13] T. Wlodarski, B. Zagrovic, Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin, *Proc. Natl. Acad. Sci. USA* 106 (2009) 19346–19351.
- [14] V. A. Braz, M. D. Barkley, R. A. Jockusch, P. L. Wintrode, Efavirenz binding site in HIV-1 reverse transcriptase monomers, *Biochemistry* 49 (2010) 10565–10573.
- [15] L. R. Masterson, C. Cheng, T. Yu, M. Tonelli, A. Kornev, S. S. Taylor, G. Veglia, Dynamics connect substrate recognition to catalysis in protein kinase A, *Nat. Chem. Biol.* 6 (2010) 821–828.
- [16] T. R. Weikl, D. D. Boehr, Conformational selection and induced changes along the catalytic cycle of *Escherichia coli* dihydrofolate reductase, *Proteins* 80 (2012) 2369–2383.
- [17] C. J. Tsai, S. Kumar, B. Ma, R. Nussinov, Folding funnels, binding funnels, and protein function, *Protein Sci.* 8 (1999) 1181–1190.
- [18] S. Kumar, B. Ma, C. J. Tsai, N. Sinha, R. Nussinov, Folding and binding cascades: dynamic landscapes and population shifts, *Protein Sci.* 9 (1) (2000) 10–19.
- [19] D. D. Boehr, R. Nussinov, P. E. Wright, The role of dynamic conformational ensembles in biomolecular recognition, *Nat. Chem. Biol.* 5 (2009) 789–796.
- [20] Y. Cheng, W. H. Prusoff, Relationship between the inhibition constant (K_I) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction, *Biochem. Pharmacol.* 22 (23) (1973) 3099–3108.
- [21] S. Gulnik, L. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, J. Erickson, Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure, *Biochemistry* 34 (1995) 9282–9287.
- [22] M. Prabu-Jeyabalan, E. Nalivaika, C. Schiffer, Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes, *Structure* 10 (2002) 369–381.
- [23] M. D. Altman, A. Ali, G. S. K. K. Reddy, M. N. L. Nalam, S. G. Anjum, H. Cao, S. Chellappan, V. Kairys, M. X. Fernandes, M. K. Gilson, C. A. Schiffer, T. M. Rana, B. Tidor, HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants, *J. Am. Chem. Soc.* 130 (2008) 6099–6113.
- [24] M. N. L. Nalam, A. Ali, M. D. Altman, G. S. K. K. Reddy, S. Chellappan, V. Kairys, A. Ozen, H. Cao, M. K. Gilson, B. Tidor, T. M. Rana, C. A. Schiffer, Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance, *J. Virol.* 84 (2010) 5368–5378.
- [25] E. S. Furfine, E. D'Souza, K. J. Ingold, J. J. Leban, T. Spector, D. J. Porter, Two-step binding mechanism for HIV protease inhibitors, *Biochemistry* 31 (1992) 7886–7891.
- [26] A. Gustchina, I. T. Weber, Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap, *FEBS Lett.* 269 (1990) 269–272.
- [27] L. Nicholson, T. Yamazaki, D. Torchia, S. Grzesiek, A. Bax, S. Stahl, J. Kaufman, P. Wingfield, P. Lam, P. Jadhav, C. Hodge, P. Domaille, C. Chang, Flexibility and function in HIV-1 protease, *Nat. Struct. Biol.* 2 (1995) 274–280.
- [28] R. Ishima, D. Freedberg, Y. Wang, J. Louis, D. Torchia, Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function, *Structure* 7 (1999) 1047–1055.
- [29] D. Freedberg, R. Ishima, J. Jacob, Y. Wang, I. Kustanovich, J. Louis, D. Torchia, Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations, *Protein Sci.* 11 (2002) 221–232.
- [30] L. Galiano, M. Bonora, G. E. Fanucci, Interflap distances in HIV-1 protease determined by pulsed EPR measurements, *J. Am. Chem. Soc.* 129 (2007) 11004–1005.
- [31] V. Y. Torbeev, H. Raghuraman, K. Mandal, S. Senapati, E. Perozo, S. B. H. Kent, Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy, *J. Am. Chem. Soc.* 131 (2009) 884–885.
- [32] M. E. Blackburn, A. M. Vero, G. E. Fanucci, Monitoring inhibitor-induced conformational population shifts in HIV-1 protease by pulsed epr spectroscopy, *Biochemistry* 48 (2009) 8765–8767.
- [33] J. Collins, S. Burt, J. Erickson, Flap opening in HIV-1 protease simulated by activated molecular-dynamics, *Nat. Struct. Biol.* 2 (1995) 334–338.
- [34] W. Scott, C. Schiffer, Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance, *Structure* 8 (2000) 1259–1265.
- [35] S. Piana, P. Carloni, U. Rothlisberger, Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations, *Protein Sci.* 11 (2002) 2393–2402.
- [36] A. Perryman, J. Lin, J. McCammon, HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs, *Protein Sci.* 13 (2004) 1108–1123.
- [37] V. Hornak, A. Okur, R. Rizzo, C. Simmerling, HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations, *Proc. Natl. Acad. Sci. USA* 103 (2006) 915–920.
- [38] A. P. Wiley, S. L. Williams, J. W. Essex, Conformational motions of HIV-1 protease identified using reversible digitally filtered molecular dynamics, *J. Chem. Theory Comput.* 5 (2009) 1117–1128.
- [39] S. Kashif Sadiq, G. De Fabritiis, Explicit solvent dynamics and energetics of HIV-1 protease flap opening and closing, *Proteins* 78 (2010) 2873–2885.
- [40] A. Genoni, G. Morra, J. Merz, Kenneth M., G. Colombo, Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors, *Biochemistry* 49 (2010) 4283–4295.
- [41] N.-J. Deng, W. Zheng, E. Gallicchio, R. M. Levy, Insights into the dynamics of HIV-1 protease: a kinetic network model constructed from atomistic simulations, *J. Am. Chem. Soc.* 133 (24) (2011) 9387–94.
- [42] B. Maschera, G. Darby, G. Palú, L. L. Wright, M. Tisdale, R. Myers, E. D. Blair, E. S. Furfine, Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex, *J. Biol. Chem.* 271 (1996) 33231–33235.
- [43] R. Rose, C. Craik, R. Stroud, Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations, *Biochemistry* 37 (1998) 2607–2621.
- [44] L. Hong, X. C. Zhang, J. A. Hartsuck, J. Tang, Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance, *Protein Sci.* 9 (2000) 1898–1904.
- [45] B. Mahalingam, J. Louis, J. Hung, R. Harrison, I. Weber, Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes, *Proteins* 43 (2001) 455–464.
- [46] H. Ode, S. Neya, M. Hata, W. Sugiura, T. Hoshino, Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M, *J. Am. Chem. Soc.* 128 (2006) 7887–7895.
- [47] A. Y. Kovalevsky, Y. Tie, F. Liu, P. I. Boross, Y.-F. Wang, S. Leshchenko, A. K. Ghosh, R. W. Harrison, I. T. Weber, Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M, *J. Med. Chem.* 49 (2006) 1379–1387.
- [48] D. Xie, S. Gulnik, E. Gustchina, B. Yu, W. Shao, W. Qoronfleh, A. Nathan, J. Erickson, Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH, *Protein Sci.* 8 (1999) 1702–1707.
- [49] B. Mahalingam, Y. Wang, P. Boross, J. Tozser, J. Louis, R. Harrison, I. Weber, Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site, *Eur. J. Biochem.* 271 (2004) 1516–1524.
- [50] M. Kozisek, J. Bray, P. Rezacová, K. Sasková, J. Brynda, J. Pokorná, F. Mammano, L. Rulisek, J. Konvalinka, Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant hiv protease mutants, *J. Mol. Biol.* 374 (2007) 1005–10016.
- [51] U. Nillroth, L. Vrang, P. Markgren, J. Hulten, A. Hallberg, U. Danielson, Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs, *Antimicrobial Agents and Chemotherapy* 41 (1997) 2383–2388.
- [52] Z. Szeltner, L. Polgar, Rate-determining steps in HIV-1 protease catalysis - The hydrolysis of the most specific substrate, *J. Biol. Chem.* 271 (1996) 32180–32184.
- [53] S. Muzammil, P. Ross, E. Freire, A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance, *Biochemistry* 42 (2003) 631–638.
- [54] C. F. Shuman, P. O. Markgren, M. Hämäläinen, U. H. Danielson, Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants, *Antiviral Res.* 58 (2003)

235–242.

- [55] T. L. Hill, Free energy transduction and biochemical cycle kinetics, Springer, New York, 1989.
- [56] T. R. Weikl, C. von Deuster, Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis, *Proteins* 75 (2009) 104–110.
- [57] J. Ermolieff, X. Lin, J. Tang, Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo, *Biochemistry* 36 (1997) 12364–12370.